Imeglimin. A New and Novel Drug Thats Better than Metformin

Key Takeaways

• Imeglimin lowers HbA1c 0.1–0.3% in pre‑diabetes baseline
• Drug prolongs erythrocyte lifespan, causing HbA1c to overstate glucose
• GA and fructosamine reveal true glycemic improvement missed by HbA1c
• Benefit diminishes when combined with potent GLP‑1RA tirzepatide
• Ongoing trials may position imeglimin as adjunct to existing therapies

Pulse Analysis

Imeglimin has emerged as the first glucose‑lowering drug that simultaneously targets insulin secretion and peripheral insulin sensitivity, positioning it as a potential successor to metformin. Its mechanism—enhancing mitochondrial NAD⁺ recycling and reducing oxidative stress—offers a biologically distinct pathway that could benefit patients who experience metformin intolerance or inadequate control. While regulatory approvals in Japan and Europe have highlighted its safety profile, the drug’s market entry in the United States remains pending, prompting clinicians to scrutinize real‑world efficacy data before broader adoption.

Clinical evidence paints a nuanced picture. In patients with baseline HbA1c around 6.9%, imeglimin achieved an average 0.2% reduction over 20 weeks, but the effect shrinks dramatically for lower baselines, such as 5.9%, where the expected drop is only 0.1–0.3%. Moreover, the INFINITY trial uncovered a pharmacodynamic quirk: imeglimin extends red‑cell lifespan, inflating HbA1c readings and obscuring genuine glucose improvements. Consequently, clinicians are urged to incorporate short‑term markers like glycated albumin or fructosamine, which bypass the erythrocyte‑related bias and provide a clearer view of therapeutic response.

From a market perspective, imeglimin’s value proposition may lie in combination regimens. When paired with powerful GLP‑1 receptor agonists such as tirzepatide, its incremental HbA1c benefit diminishes, yet it may still contribute modest hepatic gluconeogenesis suppression and mitochondrial protection. Ongoing phase‑III studies aim to define its role alongside SGLT2 inhibitors and DPP‑4 inhibitors, potentially carving out a niche as an adjunct for patients on multi‑drug protocols. If future data confirm safety and cost‑effectiveness, imeglimin could become a strategic tool for clinicians seeking to fine‑tune glycemic control without escalating metformin doses.